23 Oct 2026
Medannex Presents Further Positive Clinical Data for MDX-124 at ESMO 2026
Updated phase 1b results demonstrate 60% disease control rate, encouraging anti-tumour activity and excellent safety profile for first-in-class therapy.
Read storyMembers' News
25 Aug 2026
Weightmans - Extension of Right to Work Scheme
From 1 October 2026 UK right to work checks and liability for failing to prevent illegal working expand beyond traditional employment relationships and is being extended to include subcontractors, agency workers, zero h…
Read story3 Jun 2026
Royal Bank launches “game-changing” IP lending product
Royal Bank launches “game-changing” IP lending product for Scotland’s creatives and spinouts.
Read story3 Jun 2026
Nebuflow secures £2m Scottish Enterprise grant
Nebuflow has been awarded a £2m Scottish Enterprise grant to accelerate development and patient access to its patented nebuliser technology in the UK and globally. The technology is designed to improve how people receiv…
Read story11 May 2026
Medannex Secures SMART grant to develop a ‘biological missile’ to tackle cancers
Edinburgh-based biotechnology company Medannex today announced it has been awarded £97,000 in Scottish Enterprise SMART funding to develop a novel antibody drug conjugate (ADC) to treat pancreatic cancer and other tumou…
Read story29 Apr 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, E…
Read story13 Feb 2026
AI takes healthcare by storm: understanding how to safely launch devices in the UK, US and EU
A new whitepaper by regulatory experts IMed Group and life science software developers Firefinch Software
Read story3 Feb 2026
Innovation Leader in Cell Therapy, Sistemic, welcomes visit from Minister for Business
Sistemic Ltd, a Glasgow-based advanced molecular diagnostics company specialising in stem cell characterisation, welcomed Richard Lochhead MSP, Minister for Business and Employment, to its facilities for a ministerial v…
Read story10 Dec 2025
Sistemic part of a global initiative to progress therapeutic stem cell treatment and safety
Sistemic, specialists in Stem Cell characterisation
Read story19 Nov 2025
BioAscent and Keltic Pharma Therapeutics partner to give customers access to cutting-edge platform
BioAscent and Keltic Pharma Therapeutics partner to give customers access to cutting-edge peptide discovery platform for GPCR targets
Read story20 Oct 2025
Medannex Unveils Positive Clinical Data on MDX-124 at ESMO 2025
Medannex Ltd (Edinburgh) today announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.
Read story2 Oct 2025
Medannex’s Therapeutic Granted FDA Orphan Drug Designation for Biliary Tract Cancer
Medannex Ltd (Edinburgh) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its novel therapy MDX-124, for the treatment of biliary tract cancer (BTC).
Read story6 May 2025
BioAscent appoints Vice President of Alliance Management
BioAscent, a leading provider of integrated drug discovery and compound management services, has appointed life sciences executive leader James Hitchin as Vice President of Alliance Management. He joins BioAscent fro…
Read story21 Mar 2025
MEDANNEX UNVEILS NOVEL APPROACH TO OSTEOSARCOMA TREATMENT
Data presented at ESMO meeting demonstrate significant activity of first-in-class therapeutic
Read story11 Mar 2025
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership
RoslinCT has entered into a strategic partnership with Gamida Cell to manufacture their FDA-Approved Cell Therapy Omisirge®, a commercial product for the treatment of hematologic malignancies commercialized in the US by…
Read story